Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bipolar Androgen-based Therapy (BAT) for Recurrent Prostate Cancer
NCT01750398Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of testosterone in recurrent prostate cancer (RPC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Percent Subjects with PSA < 4 ng/ml and Without PSA Progression at 18 months. Started Jan 2013; status: completed.
02
Drugs
testosterone
03
Conditions
recurrent prostate cancer (RPC)
Beyond the preview
Go deeper on NCT01750398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01750398.